GGrantIndex
Sort

11,323 grants matching glioblastoma

Na-K-Cl cotransporter in Glioblastoma Multiforme

$327,347
Dandan Sun · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · NS

Small Molecule Antibody Mimics: Toward a New Paradigm in Targeted Cancer Therapy

$327,334
David Adam Spiegel · Yale University · R01 · FY2015 · GM

Using Cell-Penetrant Peptides to Target ATF5 in Mouse Glioma Models

$327,245
James M Angelastro · University Of California At Davis · R01 · FY2018 · NS

The Role of MMSET in DNA damage response and Chemoradioresistance

$327,228
Zhenkun Lou · Mayo Clinic Rochester · R01 · FY2010 · CA

Project 2 - Clinical translation

$327,209
Robert A Gatenby · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2019 · CA

Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBM

$327,207
Panagiotis Z Anastasiadis · Mayo Clinic Jacksonville · R01 · FY2011 · NS

Targeting Metabolic Vulnerabilities with Molecular Inhibitors of Oxidative Phosphorylation

$327,153
Florian Muller · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA

Novel Targeted Therapeutics for Cental Nervous System Malignancies

$327,069
Francis Ali-Osman · Duke University · R01 · FY2008 · CA

Enhanced Drug Delivery to Metastatic Brain Tumors

$327,038
Cedars-Sinai Medical Center · R01 · FY2004 · NS

Enhanced Drug Delivery to Metastatic Brain Tumors

$327,038
Cedars-Sinai Medical Center · R01 · FY2003 · NS

Defining the role of mutant IDH in glioma initiation and maintenance

$327,031
Sheri L. Holmen · University Of Utah · R01 · FY2012 · NS

Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma

$327,011
Hyunsuk Shim · Emory University · R21 · FY2011 · CA

GENETIC NEUROCARCINOGEN RISKS & OUTCOMES FOR BRAIN TUMOR

$326,951
Faith B Davis · Duke University · P50 · FY2006 · CA

Defining the role of BRAF in glioma initiation and maintenance

$326,940
Sheri L. Holmen · University Of Utah · R01 · FY2012 · NS

Investigation of Notch-inhibiting microRNAs in glioma

$326,937
Benjamin W. Purow · University Of Virginia · R01 · FY2009 · CA

GENETIC NEUROCARCINOGEN RISKS &OUTCOMES FOR BRAIN TUMOR

$326,912
Duke University · P50 · FY2005 · CA

Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data

$326,848
Jun S Song · University Of Illinois At Urbana-Champaign · R01 · FY2020 · CA

Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma

$326,813
Michael J Eck · Dana-Farber Cancer Inst · R01 · FY2012 · CA

Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma

$326,813
Michael J Eck · Dana-Farber Cancer Inst · R01 · FY2015 · CA

Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma

$326,813
Michael J Eck · Dana-Farber Cancer Inst · R01 · FY2016 · CA

Genetic Modulation of Cognitive Function and outcomes in Glioblastoma Patients

$326,705
Melissa L Bondy · University Of Tx Md Anderson Can Ctr · P50 · FY2010 · CA

Genetic Modulation of Cognitive Function and outcomes in Glioblastoma Patients

$326,603
Melissa L Bondy · University Of Tx Md Anderson Can Ctr · P50 · FY2012 · CA

Co-targeting mTOR and YAP signaling in glioblastoma

$326,586
Joseph F Gera · Greater Los Angeles Veterans Research And Education Foundation · R01 · FY2021 · CA

Role of cell cycle inhibitors in adult neural stem cells

$326,550
Patrizia Casaccia · Icahn School Of Medicine At Mount Sinai · R01 · FY2008 · NS

Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma

$326,489
Matthew L Meyerson · Dana-Farber Cancer Inst · R01 · FY2008 · CA